In a Series C funding round, Atreca raised $125 million, clearing the way for the company to move its first cancer immunotherapy into clinical trials.
The biotechnology firm is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes to patients suffering from solid tumors, including breast, lung, and colon cancers. The newly acquired funds will be used to advance its lead candidate ATR101 into clinical development.
“This first candidate, generated by our unique Discovery Engine and via our proprietary Immune Repertoire Capture® (IRC™) technology, represents a novel and potentially fundamental new class of oncology immunotherapeutics. We appreciate the support of both our new and existing investors as we advance the Company to this next stage of development”, said John A. Orwin, the company’s CEO.
Every moment we are alive, the body is a battlefield where immune cells are the good guys, designed to defend the body from disease and infections, while the bad guys are bacteria, pathogens, viruses and mutated cells, all of which are programmed to harm us.
Immunotherapy strengthens the immune system, enabling it to better fight against antigens. In cancer cases, the good cells mostly lose －at least for now.
Healthcare startups are advancing innovative immunotherapy treatments. For example, OncoResponse recently received $40 million in new development funding, helping doctors and patients become better equipped to successfully fight cancer and other immune related diseases.
The digital transformation of healthcare is needed in order to provide better care and treatment outcomes to patients. Researchers are bringing new ideas to the table, calling for healthcare leaders to embrace artificial intelligence and data mining to speed up innovative treatments to market.
Read the definitive guide to online reputation management for doctors